CRNX

Crinetics Pharmaceuticals Stock Analysis

AI Rating

Low
  • Quality3/10
  • Growth↓ 2/10
  • Value↓ 0/10
Crinetics Pharmaceuticals sales and earnings growth
CRNX Growth
Fair
  • Revenue Y/Y↑ 640.71%
  • EPS Y/Y↓ -34.15%
  • FCF Y/Y↓ -63.94%
Crinetics Pharmaceuticals gross and profit margin trends
CRNX Profitability
Neutral
  • Gross margin ↑ 86.00%
  • EPS margin↓ -6046.20%
  • ROIC 5Y↓ -47.54%
Crinetics Pharmaceuticals net debt vs free cash flow
CRNX Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↑ 999.0

Crinetics Pharmaceuticals stock volatility is in-line with the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗